| Robyn Zolman | ||
November 30, 2010
|
Direct: 303.298.5740 | |
| Fax: 303.313.2830 | ||
| RZolman@gibsondunn.com |
||
| Client: C 12412-00001 |
VIA EDGAR
Ms. Rose Zukin
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
| Re: | BioCryst Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2009 Filed March 9, 2010 Definitive Proxy Statement on Schedule 14A Filed April 6, 2010 File No. 000-23186 |
Dear Ms. Zukin:
On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”) this letter confirms that as discussed
with you today, the Company will respond to the Staff’s November 16, 2010 letter to the Company on
or before December 15, 2010.
Sincerely,
/s/ Robyn Zolman
Robyn Zolman
REZ/rez
| cc: | Alane Barnes, BioCryst Pharmaceuticals, Inc. Brian Lane, Gibson, Dunn & Crutcher LLP |